Loading
institutionsInstitution
Istituto di Candiolo IRCCS (FPO)
Piedmont's cancer institute near Turin, a world reference for colorectal cancer genomics, patient-derived xenografts and MET biology.
Also called: Candiolo Cancer InstituteFondazione Piemontese per l'OncologiaIRCCS CandioloINOC - Istituto Nazionale Oncologico CandioloIstituto Nazionale Oncologico Candiolo
Overview
The Candiolo Cancer Institute is a private not-for-profit IRCCS run by the Fondazione Piemontese per l'Oncologia with the University of Turin. Paolo Comoglio's laboratory discovered and characterised the MET oncogene, Livio Trusolino and Andrea Bertotti built a large colorectal cancer patient-derived xenograft platform ('xenopatients') that identified HER2 amplification as a target and led to the HERACLES trial of trastuzumab plus lapatinib, and Alberto Bardelli's group pioneered liquid biopsy tracking of resistance to anti-EGFR therapy. The hospital provides surgery, radiotherapy, medical oncology and a phase 1 unit, and hosts a large biobank and a molecular tumour board for the Piedmont network.
Location
Candiolo, IT
Type
cancer center · Università degli Studi di Torino
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#64 · 46 points (0 Newsweek + 0 NCI + 46 from 23 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-10-01.
Matched to Candiolo Cancer Institute, including child institutions. 327 works · 4,568 citations · 76% open access · 12% clinical trials · 3% reviews.
Oncology works per year
882022
892023
652024
542025
312026
Most works
- Caterina Marchiò31 works
- Livio Trusolino28 works
- Alberto Bardelli25 works
- Felice Borghi23 works
- Andrea Bertotti23 works
- Enrico Berrino21 works
- Dario Sangiolo21 works
- Enzo Médico21 works
- Filippo Montemurro20 works
- Salvatore Siena20 works
Most cited
- Colorectal cancer genomics and xenopatients
- MET oncogene biology
- Liquid biopsy and resistance
- Phase 1 trials
Alberto Bardelli
Scientific Director, IFOM ETS - The AIRC Institute of Molecular Oncology; Professor, University of Turin
Colorectal cancer genomicsLiquid biopsyAcquired resistance
Used ctDNA to show how colorectal cancers evolve resistance to EGFR antibodies and how that resistance can fade.
Andrea Agnelli
Representative of Istituto di Candiolo IRCCS (FPO) to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Andrea Agnelli represents Istituto di Candiolo IRCCS (FPO) in the Organisation of European Cancer Institutes, which lists the centre among its members in Italy.
Anna Sapino
Scientific Director
Anatomic pathologyBreast cancerMolecular pathology
Pathologist and Scientific Director of the Candiolo Cancer Institute (INOC), Piedmont's oncology IRCCS and an OECI-certified Comprehensive Cancer Centre.
rctThe Lancet Oncology 2016changed practice782 citations
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)
The first demonstration that HER2 is actionable in colorectal cancer, and the trial that defined the colorectal-specific HER2 scoring criteria every later trial has used.
methodsModern Pathology 2015changed practice245 citations
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
It is the threshold behind the colorectal HER2 approvals: the more-than-50% rule, rather than the 10% used in gastric cancer, is what a pathologist applies when a bowel cancer is called HER2-positive.
translationalNature Genetics 2015530 citations
Stromal contribution to the colorectal cancer transcriptome
It means a CMS4 call on a bulk sample partly measures how much stroma was in the block, which is both a caution for the classification and a pointer to the stroma as the thing to treat.
translationalNature 20121,525 citations
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
It made acquired resistance a measurable, plasma-readable event, and it is the origin of anti-EGFR rechallenge strategies guided by ctDNA clearance of the resistant clone.
translationalCancer Discovery 2011746 citations
A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer
It is where HER2-directed colorectal therapy came from: the xenopatient result led directly to HERACLES and therefore to every HER2 regimen now used in the disease.
Similar pages
- TrialHERACLES
Shares A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Trastuzumab.
- PersonAndrea Sartore-Bianchi
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Colorectal cancer.
- InstitutionNiguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Colorectal cancer.
- TreatmentLapatinib
Shares A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), EGFR, HER2.
- PersonSalvatore Siena
Shares Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Assessment of a HER2 scoring system for colorectal cancer: results from a validation study, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES), Colorectal cancer.
- TrialCHRONOS
Shares Circulating tumour DNA (ctDNA), EGFR, KRAS, Liquid biopsy (ctDNA).
- Key paperNILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer
Shares MET, Circulating tumour DNA (ctDNA), EGFR, HER2.
- TrialTRIUMPH
Shares Trastuzumab, Circulating tumour DNA (ctDNA), HER2, Liquid biopsy (ctDNA).
cancers
fronts
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-HER2)
Trastuzumab · Herceptin (and biosimilars, Phesgo with pertuzumab)
terms
people
bottlenecks
key papers
A molecularly annotated platform of patient-derived xenografts identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancerAssessment of a HER2 scoring system for colorectal cancer: results from a validation studyDual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerStromal contribution to the colorectal cancer transcriptome